Skip to content
Search

Latest Stories

TECHNOLOGY: Peer-to-peer dispensing

Tariq Muhammad considers how the 'hub and spoke' legislation could give rise to new innovation…

Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June.


The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time. The government also sees significant efficiency gains in centralization, arguing this will free pharmacists time away from dispensing to focus on clinical services.

The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed medication can be sent out directly to the patient.

The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.

Challenges

Hub and spoke has divided the profession with many unconvinced of the government’s calculations given that large multiples have had mixed results with their success. Whilst centralization has removed volume from the stores, this hasn’t necessarily translated into financial savings and staff often complain that waiting times have increased for patients.

Meanwhile, the cost of setting up a hub is not cheap, and many companies have already invested millions in readiness for the change in legislation. With dispensing margins so tight, the efficiency gains would have to be vast for the spoke to share their income with the hub and still ensure a decent return for both sides. Many independents are also concerned about the loss of control over their buying capability.

These are just some of the high-level barriers for hub and spoke and the day-to-day challenges are even more nuanced. For example, what do you do when a patient wants their medication before the Hub has sent it back? How do you merge packages when half of it has been dispensed in a Hub and the rest at the Spoke?

Each one of these scenarios could lead to disruption and impact the efficiency gains, so are important factors to consider if the government’s vision is to be realized.

New thinking

Despite the potential hurdles, I believe the change in legislation is a good thing. Our legislation is way out of date, too restrictive and stifles innovation. I believe the government is right to relax the laws and allow the markets to choose how they wish to exercise their freedom.

Market forces will ultimately determine whether a model is adopted or rejected. Hub and spoke may indeed work for some pharmacies and may not work for others and we should let businesses decide what suits them.

Having the freedom to dispense how we want, where we want, by whom we want, will give power to the sector to innovate new approaches. For example, what if a hub wasn’t a hub, and spoke wasn’t a spoke?

What if both were just ordinary pharmacies? Let’s imagine Pharmacy A was busy and Pharmacy B had capacity with a new robot. What if Pharmacy A was to send their prescriptions to Pharmacy B who would dispense these on their behalf and return them back?

What if there was technology that enabled all this to happen seamlessly? The change in legislation combined with innovative technology could allow us to do precisely this.

Peer-to-peer

We have always been told to imagine a hub being a large warehouse in an industrial estate with millions of pounds worth of investment and capability of dispensing millions of prescriptions. But if we think about it, there are hundreds of pharmacies up and down the country that have invested in automation for their pharmacies.

Whilst many are busy coping with their own workload, there are many that have capacity at certain times of the day (or night) where the robots are lying idle. These automated pharmacies could be given the opportunity to dispense on behalf of other local pharmacies in a peer-to-peer model.

The concept of ‘peer to peer’ dispensing has never arisen in our public discourse but has the potential to solve many of the challenges that face Hub and Spoke.

For a start, there would be practically no set up costs involved for a pharmacy wishing to offer its services to local pharmacies as all the costs have already been sunk.

This means that a servicing pharmacy could offer its services at a fraction of the cost, compared to large Hubs, as any income would be seen as an additional gain on their part. Whilst the capacity of a pharmacy to offer dispensing to others may be limited, the collective network of peers could be an undeniable force.

Technology

Needless to say, the right technology is fundamental in the creation of successful off-site dispensing models. With the right technological platform, we have the potential not only to iron out the chinks in hub and spoke but give rise to the concept of peer-to-peer dispensing.

Titan PMR has successfully broken down the stages of dispensing and the cloud operating platform has broken down the geographical boundaries between sites.

We now have the ability to clinically check a prescription in Pharmacy A and then transfer this to Pharmacy B for picking, labelling and packaging and then ensure the package is either returned back to Pharmacy A for handout or delivered directly to the patient.

Our technology today could even manage the financial transaction between Pharmacy A and B allowing each to agree their own local tariffs. So, far from being afraid of the change in legislation, we should embrace the new opportunities of hub and spoke and think beyond the challenges.

Peer-to-peer dispensing, enabled through innovative technology, could provide an alternative solution in ways we didn’t previously imagine.

Tariq Muhammad is the CEO of Invatech Health.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less